Samuel Maclean, who has lived with the lung condition for several years, is among the first to benefit ...

Pulmonary arterial hypertension (PAH) is a rare, progressive disease of the precapillary pulmonary arteries, characterized by ...

In another big-ticket licensing deal with a Chinese biotech, AstraZeneca has claimed rights to a drug candidate for chronic ...

Revuforj first-mover edge, pipeline catalysts (Niktimvo), and profitability path amid misses. Click here to read more about ...

This minimally invasive procedure offers new hope for patients who suffer from a rare type of pulmonary hypertension ...

Diagnosis years after symptoms start is a frequent occurrence in patients with pulmonary hypertension, according to a ...

Kauvery Hospital, Alwarpet, has successfully treated two failing heart valves in a patient without repeat open-heart surgery, ...

Pulmonary embolism (PE) occurs when a venous thrombus becomes lodged in lung arteries, causing impairment in oxygenation, ...

Oklahoma parents turned grief into action, working to get a law passed to improve blood clot diagnosis after their son died.

Promotion of this article has been funded by AstraZeneca UK, who had no influence on the authors or content, and reviewed for ...

Cognitive function, hand dexterity, and breathing ability play an important role in helping people with chronic obstructive ...

AstraZeneca will pay a subsidiary of Sino Biopharmaceutical $200 million upfront for the rights outside of China to an ...